Organogenesis Holdings Inc.
- Last sale
- Nov 12, 2026 · -8.46%
- Market cap
- $125.35M
- 129.8M shares
- Filings
- 673
Q3 2026+17.0% FY25 yoy
Q3 2026+4,201.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−30.9% FY25 yoy
- $125.35M
- —
- 0.4×
- 1.0×
- -0.05%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $564,169,000 | reported | |
| FY 2024 | 2024-12-31 | $482,043,000 | reported | |
| FY 2023 | 2023-12-31 | $433,140,000 | reported | |
| FY 2022 | 2022-12-31 | $450,893,000 | reported | |
| FY 2021 | 2021-12-31 | $467,359,000 revised | reported | |
| FY 2020 | 2020-12-31 | $338,298,000 | reported | |
| FY 2019 | 2019-12-31 | $260,981,000 | reported | |
| FY 2018 | 2018-12-31 | $193,449,000 | reported | |
| FY 2017 | 2017-12-31 | $198,508,000 revised | reported | |
| FY 2016 | 2016-12-31 | $138,732,000 revised | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | — | $25.48M | $25.48M | — | 126.85M sh | −3.9% | 610.1% |
| FY2023 | — | $0.00 | $0.00 | — | 131.96M sh | +0.6% | 0.0% |
| FY2022 | — | $0.00 | $0.00 | — | 131.18M sh | +1.6% | — |
Segments
Products
LineFY2025ShareChange
Net product revenue$563.03M100%+16.8%
Grant income$1.14M0.2%—
Advanced Wound Care———
Surgical & Sports Medicine———
Total$564.17M
Pharmaceutical preparations
Organogenesis Holdings Inc. is the 52nd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
AXSMAxsome Therapeutics, Inc.$638.5M65.5%28.7%$7.6BTGTXTG Therapeutics, Inc.$616.3M87.3%72.6%$9.8BOPKOpko Health, Inc.$606.9M14.9%37.2%$1.2BINSMInsmed Inc$606.4M66.7%210.5%$25.9B
ORGOOrganogenesis Holdings Inc. (this company)$564.2M17.0%6.6%$125.3M
HCMHUTCHMED (China) Ltd$548.5M13.0%83.3%$2.6BMIRMMirum Pharmaceuticals, Inc.$521.3M54.7%4.5%$6.1BBBIOBridgeBio Pharma, Inc.$502.1M126.3%144.4%$14.6BTVTXTravere Therapeutics, Inc.$490.7M110.5%5.2%$5.0BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Organogenesis Holdings Inc. · CIK 1661181 · Engraved from SEC EDGAR